Eva Lin

Johns Hopkins University — United States

Immunology and Microbiology · Life Sciences

2h-index54citations51works1.12yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

interferon and immune responses(20), Viral Infections and Vectors(15), RNA modifications and cancer(7), Mosquito-borne diseases and control(5), Lung Cancer Treatments and Mutations(4)

Publications51 total

Supplemental Figure 3 from KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077)

2025Open Access

Supplemental Figure 2 from KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077)

2025Open Access

Supplemental Dataset 1 from KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077)

2025Open Access

Supplemental Table 3 from KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077)

2025Open Access

Supplemental Figure 5 from KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077)

2025Open Access

Supplemental Figure 1 from KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077)

2025Open Access

Supplemental Table 2 from KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077)

2025Open Access

Supplemental Table 1 from KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077)

2025Open Access

Supplemental Figure 4 from KRAS Codon-Specific Mutations Differentially Toggle PI3K Pathway Signaling and Alter Sensitivity to Inavolisib (GDC-0077)

2025Open Access

PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA -Mutated Solid Tumors and in Preclinical Models

Clinical Cancer Research·2025Open Access

Data from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

1 cited

2025· 1 citedOpen Access

Supplementary Figure S2 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

2025Open Access

Supplementary Figure S3 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

2025Open Access

Supplementary Figure S1 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

2025Open Access

Supplementary Table S1 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

2025Open Access

Supplementary Figure S4 from RIT1M90I Is a Driver of Lung Adenocarcinoma Tumorigenesis and Resistance to Targeted Therapy

2025Open Access

Abstract P06: Cellular-resolution Multiplexed-CNV FISH Captures Spatial Copy Number Heterogeneity and Clonal Architecture of Colorectal Cancer

Cancer Research·2025

Abstract P36: The Intrinsically Disordered Activation Function 1 of Progesterone Receptor is Required for Regulation of Cell Proliferation

Cancer Research·2025

Abstract LT02: CRISPR-Cas9 as a Novel Cancer Gene Therapy Approach against Pancreatic Cancers

Cancer Research·2025

Abstract P22: Progestin (R5020) Induced Cell Apoptosis Via Mitochondria-Mediated Cell Death Pathway In MCF-7 Cell With PRB Overexpression

Cancer Research·2025

page 1 of 3Next →

Frequent Co-authors

Scott E. Martin(34), J. K. Lim(20), Ryan Rodriguez(20), Katherine Williams(20), John Silva(20), Paul Tyler(20), Faezzah Baharom(20), Tao Sun(20), Brandon D. Kayser(20), Robert J. Johnston(20), Ira Mellman(20), Lélia Delamarre(20), Nathaniel R. West(20), Sören Müller(20), Yan Qu(20), Klaus Heger(20), Alan G. Gutierrez(19), Nicole M. Sodir(18), Danilo Maddalo(18), Jeff Lau(16)